Join to View Full Profile
460 W 10th AveColumbus, OH 43210
Phone+1 614-293-3196
Fax+1 614-293-7526
Dr. Denlinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalResidency, Internal Medicine, 2015 - 2018
Ohio University Heritage College of Osteopathic Medicine in AthensClass of 2015
Certifications & Licensure
OH State License 2015 - 2025
American Board of Internal Medicine Internal Medicine
Clinical Trials
- DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Roles: Contact
- CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma Start of enrollment: 2024 Jan 29
Roles: Sponsor-Investigator
Publications & Presentations
PubMed
- Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies.Elvira Umyarova, Charles Pei, William Pellegrino, Qiuhong Zhao, Nidhi Sharma
Journal of Hematology & Oncology. 2025-03-18 - 2 citationsSiltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder
Blood Advances. 2025-01-14 - SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program.Timothy J Voorhees, Evandro Bezerra, Nathan Denlinger, Samantha Jaglowski, Marcos de Lima
Clinical Lymphoma, Myeloma & Leukemia. 2024-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
